Kangstem Biotech Obtains Domestic Patent for Large-Scale Cultivation Technology of Adult Stem Cells
[Asia Economy Reporter Minji Lee] Kangstem Biotech announced on the 26th that it has obtained a domestic patent for its technology to develop high-performance adult stem cells, promoting proliferation, multipotency, and reprogramming.
This patent establishes standardized culture conditions through spherical growth that maintain an undifferentiated state, enabling the production of adult stem cells with CD49f-positive characteristics that promote stem cell proliferation, multipotency, and reprogramming without undergoing costly steps in the process.
Hot Picks Today
![NPS Moves the KOSPI: How Much Will It Need to Sell If the Index Surpasses 9,000? [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052907574480845_1780009064.png)
NPS Moves the KOSPI: How Much Will It Need to Sell If the Index Surpasses 9,000? [Weekend Money]
- "Why Securities Analysts Expect the KOSPI to Hit 9,500 Next Week [Weekend Money]"
- Coach Hong Myung-Bo, Who Vowed "Final Contribution," Faces Controversy Over Estimated 3.8 Billion Won Salary
- Home Prices Defy Ultra-Strong Regulations... Seoul Apartment Prices Surge 15% in First Year of Lee Administration
- Two Typhoons Make Landfall Simultaneously, Earthquake Risk Looms... Record 250mm Per Hour Downpour Hits Japan
The company stated, "Based on this, we will be able to manufacture highly efficient stem cell therapeutics," adding, "It can also be used for the treatment of immune-related diseases as well as neurological, cardiovascular, and skeletal system disorders."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
